Inovio receives multiple awards at World Vaccine Congress 2013
Inovio received the Best Therapeutic Vaccines award for its VGX-3100 vaccine, a DNA vaccine designed to treat HPV-caused cervical dysplasia. The company also won the Best Early Stage Biotech award, which highlighted the advancement of Inovio's proprietary SynCon DNA vaccine and electroporation delivery technologies.
The ViE Awards recognize outstanding vaccine achievements and advancements by vaccine developers throughout the global industry as judged by a panel of stakeholders in the biotech industry.
"We greatly appreciate the World Vaccine Congress' recognition of Inovio's leadership and innovation in advancing what we hope and expect to become a vital new generation of immune-system-stimulating technology: DNA vaccines," J. Joseph Kim, the president and CEO of Inovio, said. "We also appreciate the specific acknowledgement of the accomplishments of VGX-3100 and its potential to become an important new approach for treating diseases caused by HPV. We look forward to the next stages of this exciting journey to revolutionize vaccines."
Inovio is currently testing VGX-3100 to treat cervical dysplasias caused caused by HPV infection as part of a global Phase II trial. Results from the trial are expected in the first quarter of 2014. Inovio's expanding product pipeline also includes clinical programs for HIV, influenza and preclinical programs for hepatitis B, hepatitis C, malaria, prostate cancer and other chronic infectious diseases.
The World Vaccines Congress & Expo, which is in its 13th year, is one of the largest and most comprehensive events in the vaccine industry.